Phase 2 RCT in 320 participants with IBS-D: ORP-101 100 mg daily did not significantly improve the composite pain and stool consistency responder rate v placebo over 12 weeks (28.3% v 21.9%; P=.12); the 50 mg arm was stopped after interim analysis.
RCTn = 320
Singh et al. ORP-101 in Irritable Bowel Syndrome With Diarrhea: A Phase II Randomized, Controlled Trial